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Abstract. Stratification by genetic risk factors for Alzheimer’s disease (AD) may help identify groups with the greatest
disease risk. Biological changes that cause late-onset AD are likely to occur years, if not decades prior to diagnosis. Here,
we select a subset of the Generation Scotland: Scottish Family Health Study cohort in a likely preclinical age-range of
60–70 years (subset n = 3,495 with cognitive and genetic data). We test for cognitive differences by polygenic risk scores for
AD. The polygenic scores are constructed using all available SNPs, excluding those within a 500 kb distance of the APOE
locus. Additive and multiplicative effects of APOE status on these associations are investigated. Small memory decrements
were observed in those with high polygenic risk scores for AD (standardized beta –0.04, p = 0.020). These associations were
independent of APOE status. There was no difference in AD polygenic scores across APOE haplotypes (p = 0.72). Individuals
with high compared to low polygenic risk scores for AD (top and bottom 5% of the distribution) show cognitive decrements,
albeit much smaller than for APOE 44 compared to 33 individuals (2.3 versus 3.5 fewer points on the processing speed
test, and 1.8 versus 2.8 fewer points on the memory test). Polygenic risk scores for AD may help identify older individuals
at greatest risk of cognitive decline and preclinical AD.
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INTRODUCTION27
It is widely acknowledged that the europatho-28
logical hallmarks of Alzheimer’s disease (AD)29
present many years prior to diagnosis [1]. Cognitive30
∗Correspondence to: Riccardo E. Marioni, Medical Genetics
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decrements are expected to be observed closer to 31
clinical diagnosis [1]. Targeting individuals who are 32
likely to be in the earliest stages of the disease is there- 33
fore a key focus for clinical trials and interventions 34
[2–4]. 35
Age is the biggest risk factor for AD although 36
there are also genetic components to the disease. 37
The apolipoprotein gene, APOE, which is involved 38
in lipid transportation, confers the greatest known 39
genetic risk of AD [5, 6]. APOE 44 homozygotes 40
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have a 14.9 increased odds of developing dementia41
compared to those with the 33 reference haplotype42
[7]. The 4 allele has a frequency in the general pop-43
ulation of around 15% [8], implying that just over44
2% of the population are 44 homozygotes. Despite45
the well-replicated association between APOE and46
AD, relatively little is known about its functional role47
in the disease process [5], although many biological48
processes including neuroinflammation, neurotoxic-49
ity, and lipid metabolism among others have been50
highlighted [6].51
In addition to APOE, several other genes have52
been implicated in the pathogenesis of AD [9]. As53
with many other diseases, AD is a polygenic trait54
whereby many genetic polymorphisms of small effect55
are likely to contribute to the disease process [9]. One56
method that incorporates many of these variants into57
a single measure is polygenic risk scoring [10]. This58
method uses existing results from genome-wide asso-59
ciation studies (GWAS) to provide weights specific60
to each genetic polymorphism, which can then be61
applied to independent cohorts. Thus, each individual62
in an independent cohort can be assigned a genetic63
risk score that is based on potentially thousands of64
genetic variants that individually explain some frac-65
tion of the risk of AD. For example, polygenic scores66
for AD predict around 2% of the variance of AD in67
an independent cohort [11]. AD polygenic risk scores68
were also shown to discriminate best between cases69
and controls between the ages of 60 and 70 years [11].70
Given the low frequency of the 44 haplo-71
type, large sample population-based cohorts are72
required to study its effects with precision. A pre-73
vious study utilizing one such cohort, Generation74
Scotland (n = 18,337), investigated cognitive ability75
by APOE status [12]. It found evidence for poorer76
memory and processing speed in 44 homozygotes77
(compared to 33 homozygotes) in a sub-sample of78
participants aged over 60 years. These age-stratified79
findings coincide with the theoretical predictions of80
Sperling et al. [1]. Furthermore, given the prediction81
models of AD development, it is plausible that cogni-82
tive decrements predictive of AD will be most notable83
in populations between the ages of 60 and 70, i.e.,84
the decade prior to an exponential increase in AD85
diagnosis.86
The primary aim of this study is to test if there are87
cognitive decrements in those with a high polygenic88
risk of AD and to see how these effects compare with89
APOE 44 status. The analysis will focus on a sub-90
group from the Generation Scotland cohort in the age91
range of 60 to 70 years.
MATERIALS AND METHODS 92
Generation Scotland: Scottish Family Health 93
Study 94
Data came from Generation Scotland: Scottish 95
Family Health Study (hereafter referred to as Gen- 96
eration Scotland), a large population-based cohort 97
sampled from five regional centers across Scot- 98
land [13, 14]. Initial recruitment focused on 7,953 99
individuals aged between 35 and 65 years, who 100
were registered with a participating General Prac- 101
tice surgery; around 96% of the UK population is 102
registered with a general medical practitioner. Rel- 103
atives of these probands were then recruited. There 104
were up to three generations of ∼7,000 participat- 105
ing families in the study, recruited between 2006 106
and 2011, yielding a cohort of over 24,000 subjects. 107
There was no intended recruitment enrichment for 108
any disease or health condition. Details on cognitive, 109
anthropometric, and health measures were recorded. 110
A full description of the cohort and the data col- 111
lected have been reported elsewhere [13, 14] and at 112
http://www.generationscotland.org. 113
Cognitive data 114
As previously described, four domains of cognitive 115
function were assessed by single tests in nearly all 116
Generation Scotland participants (n = 21,524): pro- 117
cessing speed (Wechsler Digit Symbol Substitution 118
Test [15]), verbal declarative memory (Wechsler Log- 119
ical Memory Test; sum of immediate and delayed 120
recall of one paragraph [16]), verbal fluency (the 121
phonemic Verbal Fluency Test; using the letters C, 122
F, and L, each for one minute [17]), and vocabulary 123
(the Mill Hill Vocabulary Scale; junior and senior 124
synonyms combined [18]). As a previous Genera- 125
tion Scotland study showed evidence for age-related 126
cognitive decrements in processing speed and ver- 127
bal declarative memory but not verbal fluency or 128
vocabulary [12], we focused here on the former two 129
outcomes only. 130
Genetic data 131
Genome wide genotyping and APOE haplotyping 132
details have been described previously [12]. Briefly, 133
Generation Scotland participants were genotyped 134
with either the HumanOmniExpressExome8v1-2 A 135
or HumanOmniExpressExome-8v1 A. Quality con- 136
trol was carried out in PLINK version 1.9b2c [19, 20]. 137
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Fig. 1. Flowchart documenting the selection process of the Generation Scotland analysis cohorts.
SNPs were removed if they had a missingness rate138
>2% or a Hardy-Weinberg Equilibrium test p < 10–6.139
Duplicate samples were removed. Individuals were140
removed based on gender mismatch and missing-141
ness (>2% of genotypes missing). The subsequent142
data were combined with the 1,092 individuals of143
the 1000 Genomes population [21] prior to principal144
components being calculated in GCTA [22]. Outliers,145
defined by being more than six standard deviations146
away from the mean of the first two principal com-147
ponents, were removed [23]. This left a sample of148
20,032 participants.149
APOE haplotype status depends on the genotypes150
of two single nucleotide polymorphisms (SNPs),151
rs429358 and rs7412 that can form three possible152
haplotypes: 2, 3, and 4 [24]). Array genotyping153
of these SNPs is technically difficult and, as a result,154
they are not available on the majority of commer-155
cial arrays. SNP genotypes were thus obtained using156
Taqman technology at the Wellcome Trust Clinical157
Research Facility Genetics Core, Edinburgh. Blood158
samples from Generation Scotland participants were159
collected, processed, and stored using standard oper-160
ating procedures and managed through a laboratory161
information management system at the Wellcome162
Trust Clinical Research Facility Genetics Core, Edin-163
burgh [25]. APOE genotyping data were available on164
21,039 individuals.165
Analysis cohort166
After merging the APOE, GWAS, and cogni-167
tive data, and after excluding individuals with168
self-reported AD (or a missing value) and restrict- 169
ing the cohort to individuals aged between 60 and 170
70 years, inclusive, the analysis population con- 171
tained 3,495 participants. A flowchart documenting 172
the selection process is provided in Fig. 1. 173
Polygenic risk scores 174
Polygenic risk scores for AD were calculated using 175
the PRSice software program with LD clumping 176
parameters set to R2 > 0.25 over 250 kb sliding win- 177
dows [26]. The discovery GWAS from which the 178
SNP weights were extracted was the Stage I AD 179
GWAS analysis by Lambert et al. [27]. The Gen- 180
eration Scotland polygenic scores were generated 181
using all possible SNPs (p < 1) from the discovery 182
GWAS [27] but excluding those within a 500 kb win- 183
dow of APOE. The p < 1 selection threshold was 184
based on previous polygenic score models for AD, 185
verbal-numerical reasoning (cognitive ability), and 186
educational attainment [11, 28]. In these studies, 187
while p < 1 was not the optimal threshold for AD 188
and verbal-numerical reasoning (p < 0.5 and p < 0.05, 189
respectively), there were negligible differences with 190
the results for the p < 1 threshold. A total of 539,368 191
genotyped Generation Scotland SNPs (with MAF < 192
5%) were used to construct the score using weights 193
from the Stage I analysis of Lambert et al. [27]. The 194
Lambert et al. study was a meta-analysis GWAS of the 195
1000 Genomes imputed SNPs (nSNPs > 7,000,000). 196
After excluding 2,581 SNPs within a 500 kb region of 197
APOE, we mapped the remaining SNPs to the over- 198
lapping genotyped variants in Generation Scotland. 199
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A summary of the methods and acknowledgements200
from the discovery GWAS [27] are presented in the201
Supplementary Material.202
Ethics203
All components of Generation Scotland received204
ethical approval from the NHS Tayside Committee205
on Medical Research Ethics (REC Reference Num-206
ber: 05/S1401/89). Generation Scotland has also been207
granted Research Tissue Bank status by the Tayside208
Committee on Medical Research Ethics (REC Refer-209
ence Number: 15/0040/ES), providing generic ethical210
approval for a wide range of uses within medical211
research.212
Statistical analyses213
Linear mixed modelling was used to test for214
differences in cognitive ability by AD polygenic215
risk scores and APOE status. A mixed modelling216
framework is necessary to account for potential relat-217
edness between participants; familial relationships218
were fitted using a pedigree-based kinship matrix.219
The polygenic score was entered as either a continu-220
ous variable or as ventiles (5% groupings) of risk. A221
fully adjusted model added self-reported educational222
attainment, hypertension, stroke, diabetes, heart dis-223
ease, and depression, along with a measure of social224
deprivation (Scottish Index of Multiple Deprivation)225
[12]. A sample size of 3,495 is sufficient to detect an226
effect size with an R2 of 0.18% for a type-I error of227
= 0.05 at 80% power using a one-sided test. APOE228
was entered as a factor with e3 homozygotes as the229
reference category for all other haplotype combina-230
tions.231
All analyses were conducted in R, using the ‘pwr’,232
‘kinship2’, and ‘coxme’ packages [29–32].233
RESULTS234
Description of the polygenic risk score cohort235
(n = 3,625, age-range 60–70 years)236
A demographic summary of the target population237
aged between 60 and 70 years and with AD polygenic238
risk scores is presented in Table 1. The median age of239
the cohort was 63 (IQR 61–65) and 57% were female.240
The mean BMI of the cohort was 27.5 kg/m2 (SD 5.0).241
The median educational attainment was 12–13 years242
(measured categorically). The self-reported health243
questionnaire identified 27% of participants with244
Table 1
Summary of the Generation Scotland AD polygenic risk cohort
Polygenic risk cohort
Variable n mean sd
Age (years – median, IQR) 3,495 63 61–65
Digit Symbol Test 3,495 62.5 14.4
Logical Memory 3,495 29.5 8.0
SIMD (rank, median, IQR)∗ 3,318 4566 2924–5542
Educational attainment† 3,365 4 3–5
n %
Sex (Female) 1,998 57.2
Self-report hypertension (yes) 929 26.6
Self-report stroke (yes) 79 2.3
Self-report diabetes (yes) 194 5.6
Self-report heart disease (yes) 285 8.2
Self-report depression (yes) 298 8.5
APOE
22 19 0.5
23 437 12.5
24 86 2.5
33 2,081 59.5
34 782 22.4
44 90 2.6
∗Scottish Index of Multiple Deprivation. †Education was measured
as an ordinal variable, so median and quartiles are reported. 0 : 0
years, 1 : 1–4 years, 2 : 5–9 years, 3 : 10–11 years, 4 : 12–13 years,
5 : 14–15 years, 6 : 16–17 years, 7 : 18–19 years, 8 : 20–21 years,
9 : 22–23 years, 10:≥24 years.
self-reported hypertension, 9% with depression, 6% 245
with diabetes, 2% with stroke, and 8% with heart 246
disease. 247
Cognitive differences by AD polygenic score with 248
and without adjustment for APOE status 249
(n = 3,625, age-range 60–70 years) 250
There was a statistically significant association 251
between the polygenic score and memory (Table 2): 252
effect size of –0.31 points per SD of the polygenic 253
score, SE 0.14, p = 0.020. A similar effect size was 254
observed for processing speed although it was not sig- 255
nificantly different from the null (effect size –0.27, SE 256
0.24, p = 0.25). There was no difference in polygenic 257
score by APOE genotype (age- and sex-adjusted 258
ANOVA p = 0.72). Moreover, the effect size for the 259
polygenic score in the memory model remained sig- 260
nificant and was not attenuated after adjusting for 261
APOE haplotype (effect size –0.30 points, SE = 0.14, 262
p = 0.025); there was also no evidence for an APOE 263
x polygenic score interaction (likelihood ratio test 264
P = 0.40). Similarly, there was no evidence of an 265
APOE x polygenic score interaction for the process- 266
ing speed model (likelihood ratio test p = 0.86). In 267
the fully adjusted models, which controlled for self- 268
reported diabetes, stroke, heart disease, diabetes, and 269
Un
co
rre
cte
d A
uth
or
 P
ro
of
R.E. Marioni et al. / Genetic Stratiﬁcation and AD Risk 5
Table 2
Comparison of cognitive outcomes by genetic risk for AD and APOE status. All models adjust for age, sex,
and pedigree-based relatedness
Variable beta SE p FDR Adjusted p∗
Effect per SD of PGRS
Digit Symbol Test –0.28 0.24 0.25 0.25
Logical Memory –0.31 0.14 0.020 0.04
Top versus Bottom 5% of PGRS
Digit Symbol Test –2.32 1.54 0.13 0.15
Logical Memory –1.84 0.83 0.028 0.04
APOE 44 versus 33
Digit Symbol Test –3.51 1.53 0.022 0.04
Logical Memory –2.78 0.86 1.2 × 10–3 0.007
PGRS, Polygenic risk score; SD, standard deviation; SE, standard error. ∗False discovery rate adjusted p-values
after applying a Benjamini-Hochberg correction to the six empirical p-values.
depression, along with educational attainment and a270
social deprivation index, there was a slight increase271
in the effect size of the polygenic score on both the272
memory and processing speed measures: effect sizes273
of –0.34, SE 0.14, p = 0.014 and –0.31, SE 0.24,274
p = 0.20, respectively.275
Cognitive differences in the top versus bottom276
5% of the polygenic score distribution277
(age-range 60–70 years)278
A significant association was observed in the age-279
and sex-adjusted analyses that compared the top and280
bottom ventile (5%) of the polygenic distribution for281
memory differences. Those in the top (highest AD282
risk) ventile scored a mean of 1.8 points (SE 0.8,283
p = 0.028) lower than those in the bottom ventile on284
the memory test; for processing speed, those in the top285
ventile scored a mean of 2.3 points (SE 1.5, p = 0.13)286
lower than the bottom ventile.287
Cognitive differences by APOE status (n = 3,625,288
age-range 60–70 years)289
In a regression of cognitive ability on age, sex, and290
APOE, 44 homozygotes scored a mean of 2.8 and291
3.5 points lower on memory and processing speed292
(p = 0.001 and p = 0.022, respectively) compared to293
33 homozygotes.294
Sensitivity and secondary analyses295
While a kinship matrix was included to model296
relatedness between participants, a sensitivity anal-297
ysis on only unrelated individuals was performed.298
A genetic relationship matrix was created in GCTA299
and unrelated individuals (relationship coefficient300
<0.025) were retained (n = 2,677). In this sub-group,301
we observed results consistent with the primary anal- 302
ysis (Supplementary Table 1). 303
A second sensitivity analysis was run after exclud- 304
ing those with fewer than 5 years of education (n = 12) 305
or a missing value for education (n = 130). These 306
results were consistent with the primary analysis 307
(Supplementary Table 2). 308
To determine if cognitive decrements by AD 309
polygenic scores were present at younger ages, we 310
selected an analysis sub-cohort in the age range of 311
45 to 60 years (n = 6,853). We observed generally 312
smaller effect sizes to the 60 to 70 sub-group that 313
were all non-significant (Supplementary Table 3). 314
Similarly, we observed null associations between 315
the polygenic score and cognitive decrements in a 316
sub-group of participants aged over 70 years (Sup- 317
plementary Table 4). 318
DISCUSSION 319
In a group of over 3,000 individuals aged between 320
60 and 70 years, polygenic risk scores for AD were 321
associated with decrements for memory but not pro- 322
cessing speed. This was the case when considering 323
polygenic risk on a continuum and also when com- 324
paring the extremes (top and bottom 5%) of the 325
distribution. Furthermore, a higher AD polygenic risk 326
score was associated with an increased odds of family 327
history of AD in an extended sample of 6,724 unre- 328
lated participants of all ages. A significant association 329
was only present when comparing the extremes of 330
the distribution rather than a continuous polygenic 331
score. This increased risk was independent of APOE 332
status. Relative to 33 homozygotes (59.5% of the 333
study population), APOE 44 homozygotes (2.6% 334
of the study population) carried a lower risk of famil- 335
ial AD than those in the top 5% of the AD polygenic 336
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burden compared to those in the bottom 5%. Further-337
more, although a relatively large point estimate was338
observed in the expected direction, the 44 asso-339
ciation was not significantly associated with family340
history of AD, unlike 4 presence (versus absence).341
This is likely to be due to a lack of statistical power.342
The main limitation of the current study is the sam-343
ple size. The post hoc power calculations showed344
that the total number of participants in the 60–70 age345
range was only just sufficient to detect relatively small346
memory decrements by AD polygenic score status.347
The relatively modest association p-values for the348
primary analyses (Table 2) reflect this lack of power.349
The associations remained significant after a FDR350
correction; only the APOE association with Logical351
Memory would remain significant after a Bonferroni352
correction (p < 0.05/6).353
Another possible limitation is the construction of354
the AD polygenic risk predictor. As the number of355
cases and controls increases in the discovery GWAS356
[27], the precision and reliability of the SNP regres-357
sion weights will improve. The cross-sectional design358
of the Generation Scotland analysis may also be a359
limitation, as might the lack of information on sub-360
jective memory complaints. One recent study showed361
that a high genetic score for AD (based on 22 top362
SNP hits from a GWAS study) was associated with363
steeper decline in memory, although the magnitude364
of the effect was reduced when the APOE locus was365
removed from the score [33].366
With sufficiently large sample sizes, it is likely367
that cognitive differences in processing speed will be368
present in the general population for those with high369
versus low polygenic risk of AD. Larger discovery370
GWAS studies will also help to identify the opti-371
mal number of SNPs (all SNPs in a truly polygenic372
architecture versus a smaller number of possibly373
more biologically informative SNPs) for a polygenic374
predictor. The genetic contribution to AD has been375
shown to overlap with the genetics of education, intel-376
ligence, and income but not other health, disease,377
or psychiatric outcomes [28, 34, 35]. Intuitively, we378
would therefore expect to see phenotypic differences379
across all ranges of the polygenic scores and more380
acutely with the extremes of the distribution.381
The most comprehensive study to have examined382
the association between polygenic scores for AD383
with cognitive function [27] used a predictor based384
on the Lambert et al. discovery GWAS [11]. The385
independent target dataset in that study was the UK386
Biobank study. Small but significant associations, not387
explaining more than 0.05% of the variance in three388
cognitive traits and 0.07% of the variance in educa- 389
tional attainment [28]. 390
In conclusion, there is potential clinical utility for 391
the stratification of mid-to-late-life population-based 392
cohorts into high and low risk groups (based onAPOE 393
status and global polygenic risk) to better understand 394
the pathophysiology of AD. However, large sample 395
sizes for both the GWASs used to build the poly- 396
genic scores and to select at risk sub-groups of the 397
population are likely to be necessary. By contrast, 398
smaller sample sizes are likely to be required when 399
stratifying by APOE 44 status, as effect sizes are 400
far greater in magnitude. Nonetheless, with increas- 401
ingly powerful polygenic predictors—as a result of 402
bigger baseline GWAS studies—it seems likely that 403
the extremes of the distribution will provide high risk 404
groups equivalent to those with two 4 alleles. How- 405
ever, the extremes of the polygenic score distribution 406
will be of additional value as, by definition of their 407
construction, they will tap into genome wide risk and 408
multiple pathways that lead to AD. Longitudinal col- 409
lection of cognitive test data in addition to biomarker 410
panels and ‘omics data, such as methylomics, which 411
have been linked to AD pathology [36] may help 412
illuminate biological signatures for AD, and improve 413
long-term prediction of the disease. 414
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